Apply
Apply

Meet the 10 Finalists of 2025 Edition

  • AAV-Based Gene Therapy for PPMS – A novel Adeno-associated virus (AAV)-based gene therapy for Primary Progressive Multiple Sclerosis (PPMS). Its intravenously injected delivery system efficiently crosses the blood-brain barrier, offering a new treatment for this currently untreatable neurodegenerative disease.

    • Glioblastoma Treatment Innovation – A novel glioblastoma treatment using a patient-tailored stent (gliomaSTENT) and hybrid nanoparticles. This platform delivers targeted chemotherapy and localized heat therapy to improve drug retention and patient outcomes.

      • GnRHope – A novel cognitive-enhancing treatment approach for neurodevelopmental and neurodegenerative disorders. It aims to improve patient autonomy, aid workforce integration, and relieve caregiver burden.

          • iPLUS – A disruptive technology for biomanufacturing that doubles therapeutic protein yield. It easily integrates into vectors without altering coding sequences, simplifying regulatory compliance, seamlessly integrating into current biopharma manufacturing and boosting production.

            • mFibro – a polymeric carrier system for targeted mRNA delivery to fibroblasts. This technology aims to treat fibrotic diseases by enhancing stability and creating an efficient delivery platform.

                • NEXOLIVAD – An exosome-based therapy for Alzheimer’s, targeting the liver-brain axis. Its engineered exosomes cross the blood-brain barrier, restoring metabolic health and reducing neuroinflammation to slow disease progression.

                  • Optomics® Technology – A photonics and AI platform creating digital libraries of nano-biomarkers for rapid, label-free blood analysis, advancing Alzheimer’s diagnostics.

                    • PURR.AI’s AGELESS Platform – An AI-powered platform accelerating drug discovery for brain diseases by predicting blood-brain barrier permeability and reducing failure rates in Central Nervous System drug development.

                      • Reventus Pharma – Repositioning REV-604 to target MELAS syndrome, accelerating development for this severe mitochondrial disorder using AI-driven selection and strong preclinical data.

                        • Targeting VGF Receptor Signalling for Brain Metastasis – A dual-action small-molecule therapy designed to block key signaling pathways, preventing tumor cells from entering the brain and stopping metastasis progression at its origin.